A large study that ran from 1993–1995 with adjuvant high-dose chemotherapy and haematopoietic stem cell transplantation in patients with triple-negative breast cancer showed promising results, but lacked long-term data. To address this, a follow-up analysis has been performed. In her interview, Dr Tessa Steenbruggen reviews the results from the original study and what we can learn from this retrospective analysis. The original medical records were reviewed and questionnaires were completed by general practitioners, cardiologists, and oncologists. These data were linked to nationwide registries which resulted in comprehensive 20-year follow-up datasets. The results revealed that there was no incidence of secondary cancers or major cardiovascular events. While there was no significant overall survival benefit in the full study population, there was a significant overall survival benefit in a sub-group analysis, lending to a trend towards better overall survival in patients with triple-negative breast cancer.
1. Why have the use of high-dose chemotherapy and hematopoietic stem cell transplantation for the treatment of breast cancer not become the standard of care? (0:11)
2. Could you tell us about the design and rationale behind the original phase III study? (1:10)
3. How were the follow-up data from this phase III study collected? (2:02)
4. Could you tell us a little about the long-term data you are presenting at the ESMO 2018 congress? (2:47)
5. How are these findings likely to impact on clinical practice? (3:44)
Speaker disclosures: Tessa Steenbruggen has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Breast Cancer
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!